IRADIMED CORPORATION
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from IRADIMED CORPORATION's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales and profit both grew in each of the last 3 years. Steadier than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
$109Over the last 3 years, every $100 of reported profit came with $109 of operating cash.
Lower than 79% of Healthcare companies in United States.
Self-Funding Ratio
2.5×Over the last 3 years its own operating cash covered its investment spending (capex) 2.5 times.
Higher than 77% of Healthcare companies in United States.
Cash Locked Ratio
$26For every $100 of sales, $26 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $31 tied up three years earlier.
More money tied up than 56% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
$32Sales grew 57% in 3 years; of every extra $100 of sales, $32 became extra profit.
Higher than 58% of Healthcare companies in United States.
Asset Productivity Ratio
+57% / +27%In 3 years sales changed by +57% while total assets changed by +27%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+5%Cash, after subtracting all debt, equals 5% of its market value (net cash).
Lower than 58% of Healthcare companies in United States.
Tangible Assets Ratio
97%Of every $100 the company owns, $97 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 79% of Healthcare companies in United States.
Tangible Net Worth Ratio
96%Of every $100 of net worth, $96 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 84% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
IRADIMED CORPORATION owes $0.12 for every $1 it owns. Net profit rose 17% in the year to Dec 2025, and grew 21% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
49.0Investors pay $49.0 for every $1 of IRADIMED CORPORATION's yearly profit, higher than 80% of Healthcare companies in United States.
P/B ratio
11.01The share price is 11.01 times IRADIMED CORPORATION's book value per share, higher than 88% of Healthcare companies in United States.
Market cap
$1.1 BThe total market value of all of IRADIMED CORPORATION's shares at today's price (share price × number of shares), larger than 65% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$102 MWhat IRADIMED CORPORATION would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$7.96Net worth divided by the number of shares. The share price of $87.64 is 11.0 times this, which is the P/B above.
Return on equity (ROE)
23.5%IRADIMED CORPORATION earned 23.5% on its shareholders' money over the last year, higher than 92% of Healthcare companies in United States.
Owes vs Owns
0.12×IRADIMED CORPORATION owes $0.12 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Dividend yield
0.91%IRADIMED CORPORATION pays 0.91% of its share price as dividends a year, lower than 55% of dividend-paying Healthcare companies in United States.
Revenue growth
+14%Revenue rose 14% in the year to Dec 2025, and grew 16% a year on average over 3 years.
Profit growth
+17%Net profit rose 17% in the year to Dec 2025, and grew 21% a year on average over 3 years.
Profit margin
26.8%IRADIMED CORPORATION keeps $27 of every $100 of revenue as net profit.
Cash quality
1.1×Cash from IRADIMED CORPORATION's business was 1.1× its reported profit in the year to Dec 2025 — its profit turned into cash.
Cash vs debt
Net cashIRADIMED CORPORATION held $51 M more cash than debt (net cash) at Dec 2025.
Questions
What is IRADIMED CORPORATION's P/E ratio?
Investors pay $49.0 for every $1 of IRADIMED CORPORATION's yearly profit, higher than 80% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For IRADIMED CORPORATION: $1.1 B ÷ $102 M (30 Jun 2026) = 11.0.
What is IRADIMED CORPORATION's return on equity?
IRADIMED CORPORATION earned 23.5% on its shareholders' money over the last year, higher than 92% of Healthcare companies in United States.
How much does IRADIMED CORPORATION owe compared with what it owns?
IRADIMED CORPORATION owes $0.12 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Does IRADIMED CORPORATION pay a dividend?
Yes. IRADIMED CORPORATION pays 0.91% of its share price as dividends a year, lower than 55% of dividend-paying Healthcare companies in United States.
Is IRADIMED CORPORATION's revenue growing?
Revenue rose 14% in the year to Dec 2025, and grew 16% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.